Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexosome cancer immunotherapy - Institute Gustave-Roussy/Therapeutics Solutions International

Next Previous
X
Search
Drug Profile

Dexosome cancer immunotherapy - Institute Gustave-Roussy/Therapeutics Solutions International

Alternative Names: Autologous dendritic cell-derived exosomes; DEX

Latest Information Update: 31 Dec 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute Gustave-Roussy
  • Developer Duke University Medical Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 25 Jan 2016 Dexosome cancer immunotherapy product licensed to Therapeutic Solutions International
  • 25 Jan 2016 Therapeutic Solutions International in-licenses patent for dexosome cancer immunotherapy
  • 31 Jan 2007 Discontinued - Phase-I/II for Lung cancer in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top